Development of Vitiligo in Patients Treated with BRAF/MEK Inhibitors: A Systematic Review
Published: 14 July 2023| Version 2 | DOI: 10.17632/gvzfkkjyks.2
Contributor:
Nancy LiuDescription
BRAF and MEK inhibitors have emerged as key therapies in the treatment of metastatic melanoma through selective inhibition of the mitogen activated protein kinase (MAPK) pathway. A rare side effect of BRAF and MEK inhibitors is the development of vitiligo. This systematic review aims to summarize the existing literature on new-onset or exacerbations of vitiligo following BRAF, MEK, or BRAF/MEK combination inhibitor therapy.
Files
Categories
Dermatology